



EUROPE

IPXX

2021

**World Series of Industry
and Investor Partnering
Conferences**

**Focusing on Diagnostics, Digital Health,
Precision Medicine and Life Science Tools**

ADVERTISEMENT



**McDermott
Will & Emery**

HELPING LIFE SCIENCE LEADERS ACHIEVE THEIR MISSION.

We know it's mission that drives you. Whether you're a cutting-edge diagnostics start-up or a global leader in the industry, our team provides the full range of legal services to help you overcome obstacles, enter new markets and take advantage of opportunities on your path to success.

[MWE.COM/LIFESCIENCES](https://www.mwe.com/lifesciences)

©2021 McDermott Will & Emery. For a complete list of entities visit [mwe.com/legalnotices](https://www.mwe.com/legalnotices).
This may be considered attorney advertising. Prior results do not guarantee a similar outcome.



Contents

2
Editorial

3
DxPx portrait

6
Agenda for November 16

7
DxPx Insights

9
Speaker

12
Diagnostics4Life - Charity project

13
42PLUS1 Pitch Award

17
Interview Marc Rippen, Alertgy

20
Contact

21
Outlook & save the dates 2022



ADVERTISEMENT



Investment banking and financial advisory services for the global middle market

DIAGNOSTICS & RESEARCH TOOLS

- Instruments & Devices
- Point-of-Care Diagnostics
- Controls, Reagents, & Consumables
- Lab Equipment & Supplies
- Lab Automation & Sample Prep
- Drug Discovery Tools
- Pharmaceutical Services & Outsourcing



John C. Riddle
Managing Director & Principal
Head of Healthcare & Life Sciences
312.658.4758
jriddle@bglco.com



Christoph R. Brandenberger
Managing Director
Diagnostics & Device
312.658.4773
cbrandenberger@bglco.com

Mergers & Acquisitions • Capital Markets • Financial Restructuring
Valuations & Opinions • Real Estate



Transactions involving securities are conducted at the Chicago and Cleveland offices. Brown, Gibbons, Lang & Company Securities, Inc., an affiliate of Brown Gibbons Lang & Company LLC, is a registered broker-dealer and member of FINRA and SIPC.

Dear Readers,

The past two years have demonstrated the immense relevance of our industry to combat a worldwide pandemic. Novel diagnostic tests helped to identify and condemn outbreaks, digital health solutions aided patients suffering from the long-Covid syndrome, and life science tools played a critical role in the manufacturing of vaccines.

Never before has an entire industry responded so swiftly and effectively to a new public health threat. From the first recorded Covid patients in December 2019, it only took a few months until large diagnostic players such as Roche and Danaher were able to offer Covid tests. To support R&D efforts, over €1 Billion were provided by the European Union alone, with plans to raise investments by an extra 3.6 billion until 2027. Further, during the last year venture capital investments spiked and we saw some high-value acquisitions in the diagnostics space. It will be interesting to follow how this increased funding and the new partnerships will translate into innovations and ultimately new solutions for patients and the healthcare system.

Partnerships have always been a success factor in our industry and with more innovative solutions becoming available, we expect to see their impact multiply across different health sectors and to the end-users. At DxPx, we are proud that we can support international partnering with a dedicated focus on the four interrelated industries - diagnostics, digital health, precision medicine, and life science tools. Expanding the DxPx to the US earlier this year was an important milestones for us to support matchmaking between investors, entrepreneurs and industrial leaders worldwide. In parallel, we are ecstatic that we were able to further grow the funding of our Pitch Award, 42PLUS1, to \$2,000,000, to support innovative startups and growth companies.

Finally, I want to inform you about our DxPx charity platform – Diagnostics4Life, which holds a dear place in my heart. With Dx4Life we want to give something back while continuing to raise awareness on innovative technologies and the value our industry provides to our society. For this reason, we will donate 10% of the income that DxPx generates from ticket sales and sponsoring from our industry partners, to help patients who heavily depend on diagnostics to improve their quality of life. You can find further information on www.diagnostics4life.org and we are of course happy to find additional partners to support this endeavor during next year's events - either as a participant, sponsor or knowledge partner.

Best regards,



Mirko Stange
DxPx Initiator


4th DxPx – and after 2 years break finally in person again

How it all started


The founders of DxPx are all startup entrepreneurs and former industry executives who had the idea for this conference after having attended numerous partnering events where the vast majority of participants and investors were focused on pharma, biotech, and drug screening opportunities.

DxPx was first launched in 2019, as a physical event managed independently, yet parallel, to the MEDICA Trade fair in Dusseldorf, Germany. At this time, Covid was unheard of and with over 400 participants attending the conference physically we were already planning to expand partnering. Of course, the past 24 months required us to explore other means to facilitate net-

Industry focus of our DxPx participants



Investor types participating at DxPx



working. Today, we believe that a combination of several days of digital partnering with a dedicated day for on-site meetings, panels and fireside chats combines the best of two worlds. We also look forward to introducing additional partnering features over the course of next year.

With the gaining importance of diagnostics, digital health, precision medicine, and life science tools, we are convinced that there is a need for a dedicated platform to bring together the relevant stakeholders to further drive innovations and partnerships in our industries.

With the support of industry sponsors such as Roche Diagnostics and Hologic and our Knowledge Partners McDermott Will & Emery, Brown Gibbons Lang & Company, McKinsey & Company and Prequin DxPx continues to grow and for the first time expanded in 2021 to the US. Please stay tuned as we will continue this journey to other regions in the future.

OVER 1,000
ONE-TO-ONE MEETINGS

MORE THAN 30
COUNTRIES PARTICIPATING

10 HOURS
FIRESIDE CHATS AND PANEL DISCUSSIONS

8 DAYS
DIGITAL AND ON-SITE PARTNERING

1 FOCUS
**ON DIAGNOSTICS, DIGITAL HEALTH,
PRECISION MEDICINE AND LIFE SCIENCE TOOLS**

Recap previous events with our

DxPx Impressions



Agenda for the on-site conference day - November 16th

A day of hands-on talks

- | | |
|---|---|
| 7:30 am - 8:50 am
DxPx Insights | INTERNATIONAL MARKETS AND TRANSACTIONS BRIEFINGS
with our Knowledge Partners |
| 9:00 am - 9:05 am
Opening Speech | WELCOME TO DxPx 2021
Dr. Mirko Stange, DxPx Initiator, Silversky LifeSciences |
| 9:05 am - 9:30 am
Keynote | TRANSFORMING COMMUNITY BASED HEALTHCARE
- a novel point of care platform from concept to NASDAQ listing
David Walton, CCO, LumiraDx |
| 10:00 am - 10:40 am
Fireside Chat | NEW TECHNOLOGIES AND HOW TO BRING THEM TO MARKET
Jason Gammack, CEO, Resolve BioSciences
interviewed by Deniz Tschammler, McDermott Will & Emery |
| 11:00 am - 11:40 am
Fireside Chat | THE EVOLUTION OF DIAGNOSTICS
- from testing solutions to patient management and monitoring.
Ruedi Stoffel, Partnering Network Lead, Roch
interviewed by Erika Stanzl, McKinsey & Company |
| 1:00 pm - 1:40 pm
Panel Discussion | INVESTMENT TRENDS
- in the Diagnostics, Digital Health, Precision Medicine & Life Science Tools industry
Andreea Paslaru (Roche), Maximilian Scholz (Plug&Play),
Cornelius Maas (SHS Capital),
Moderator: Arturo Urrios, Wellington Partners |
| 2:00 pm - 4:00 pm
Pitch Award | 42PLUS1 FINALE
where 8 finalists, from all over the world, pitch for 2,000,000 USD funding |
| 4:20 pm - 4:40 pm
State of the industry | WHAT'S NEXT FOR THE VENTURE CAPITAL INDUSTRY
Cameron Joyce, Vice President Research Insights, Preqin |
| 4:40 pm - 5:00 pm
Donation handover | DxPx CHARITY PROJECT: DIAGNOSTICS4LIFE
- supporting the Elterninitiative herzkranker Kinder, Köln e.V.
Anna Paul, Representative, Elterninitiative herzkranker Kinder, Köln e.V.
handover done by Mirko Stange, Silversky LifeSciences |
| 5:00 pm - 6:00 pm
Closing | RECEPTION
including the announcement of the 42PLUS1 Pitch Award winners |

FROM 6:30 PM
ROOFTOP AFTERPARTY
AT ME&ALL HOTEL DUSSELDORF,

(FOR REGISTRATION PLEASE CONTACT: REGISTRATION@DXPX-CONFERENCE.COM)



International markets and transactions briefing

“The early bird gets the worm” is a proverb that emphasizes the importance of starting something early to maximize the potential outcome.

At the DxPx flagship event in Duesseldorf, we therefore offer the „DxPx Insights – an International Markets & Transactions Briefing“ starting at 7:30 am before the official partnerin

As an exclusive executive-only event it offers vital insights shared by our knowledge partners and industry leaders on the latest trends, provides solutions on obstacles, and high-value insights stemming from multiple 100s of years of combined experience.

Life after COVID. What are the lasting changes in Healthcare and Diagnostics?

Christoph Brandenberger, Brown Gibbons Lang & Company

The acquisition of health data bases and pitfalls for investors from a data protection standpoint.

Angus McQuilken, McDermott Will & Emery

Diagnostics and Real World Data – Building an ecosystem that takes us even closer to precision care.

Erica Stanzl, McKinsey & Company



The most insightful breakfast you can have

Our Knowledge Partners

CHRISTOPH BRANDENBERGER

Managing Director

Brown Gibbons Lang & Company (BGL) is a leading independent investment bank and financial advisory firm focusing on the global middle market for more than 30 years. As a knowledge partner of DxPx since 2019, BGL promotes cross-border support, servicing clients in more than 30 countries.



BROWN GIBBONS
LANG & COMPANY

ANGUS MCQUILKEN

Industry Relation Executive

McDermott Will & Emery is a legal advisor that partners with leaders around the world to fuel missions, knock down barriers, and shape markets. With 20+ locations globally, their team works seamlessly across practices, industries, and geographies to as knowledge partner of DxPx help the conference expand to new territories.



McDermott
Will & Emery

ERIKA STANZL

Associate Partner

McKinsey & Company is a global management consulting firm, helping leading organizations across the private, public, and social sectors, create the change that matters most to them. With the increasing value of the health diagnostics sector, McKinsey offers valuable advice on future trends in the DxPx relevant industries.



McKinsey
& Company

CAMERON JOYCE

Vice President

Preqin is the Home of Alternatives, the foremost provider of data, analytics, and insights to the alternative assets community. Their flagship platform is Preqin Pro, the largest and most versatile data and analytics source for alternatives, while also producing market-leading research reports, analytics, and tools. As a knowledge partner of DxPx, they offer valuable market insights.



@preqin

SILVERSKY LIFESCIENCES

DxPx Initiator

Silversky is a leading company builder that also offers fundraising and M&A support for clients from the diagnostics, digital health, precision medicine, and life science tools field. All partners of Silversky have their own experience as founders in the life science sector and have initiated DxPx & the 42PLUS1 Pitch Award to help other entrepreneurs find the right investors and partners more effectively



DxPx Insights

It's not just our great speakers.



David Walton
CCO



Jason Gammack
CEO



Deniz Tschammler
Counsel in Health and Life Sciences



Ruedi Stoffe
Partnering Network Lead



Andreea Paslaru
Director Partnering Customer Area Network Lead



Maximilian Scholz
Investor & Venture Capital Analyst



Cornelius Maas
Partner



Anna Paul
Representative



“Highly effective networking event with global relevance & attendance. Great conversations expanding our visibility of innovative technologies & promising business models.”

Daniel Nothelfer, Danaher Life Sciences, Germany, Vice President.

But also over 1,000 One-to-One Meetings with investors and business partners.



“Thanks for this great event. I truly enjoyed it. The format facilitated deep and very efficient interaction with potential partners.”

Dr. Babette Güldenpfennig, Roche Diagnostics, Switzerland, Head of Global Licensing.

Quotes from our last physical DxPx Conference

China Spotlight powered by Roche: Takeaway notes from Chinese investors and startups - Macro-environment of Diagnostics in China



Philip Huang
Vice President




Ray Sun
General Manager



Recap previous events with our

DxPx Impressions



DxPx is proud to announce our first charity project

Diagnostics4Life

The initiators of DxPx have always been driven by the idea of improving the healthcare system. For these reasons they have founded and built several diagnostics & life science tools startups as entrepreneurs. By establishing DxPx they aim to improve financing & M&A transactions to ensure that much-needed innovations get to market.

In 2021 we, therefore, decided to work together with the parents' initiative for children born with heart disease in Cologne (Elterninitiative herzkranker Kinder Köln e.V. [EI]). Even though diagnostics is becoming more accurate and better, heart defects in prenatal diagnostics remain undetected in 50 percent of cases. Almost 8,000 children in Germany alone are involved per year with some life-threatening heart defects and about half of these need the support of heart-lung machines or open-heart surgeries during the first days of their lives.

The Elterninitiative herzkranker Kinder Köln e.V. (EI) plays a critical role in providing hands-on and financial support to help the affected children and their families.

Via Diagnostics4Life, the DxPx initiators will donate 10% of the proceeds earned from industry partners including sponsoring funds. Every Dollar / EURO goes directly to the children and their families. Please contact us to recommend a charity organization in the US that we could approach as a partner for the DxPx US. Also, please contact us directly if you want to support this initiative – either as a media partner, by sharing content, or as a DxPx industry partner for 2022.





**EUROPE'S HIGHEST PRIZED
PITCH AWARD**

**\$2,000,000
IN FUNDING**

**338
STARTUPS**

**45
COUNTRIES**

**8
FINALISTS**

**1
GRAND FINALE
AT DXPX EU**

The startup universe is big. Really big.

THERE'S NOT ONLY MAGIC HAPPENING,
BUT ALSO MONEY TO WIN, PRESTIGE TO
CONQUER, AND AWARENESS TO BUILD!

DxPx has always been aiming for one goal: foster innovation and offer start-ups and growth companies a chance to connect with the most suitable investors and industry leaders. The next step on our way, to achieve that goal, was to build the highest prized pitch award in the world of diagnostics, digital health, precision medicine, and research tools – our 42PLUS1.

The idea behind 42PLUS1 is simple. 42 is known as the answer to the ultimate question of life, the universe, and everything. We help with another, very specific answer to one question: “How am I to find investors and become visible among the many stars of the ever-growing startup universe?”

With 42PLUS1, we want to make it exactly that easier and help where we have the biggest impact. So we focus on startups of the DxPx galaxy, being a home to the diagnostics, digital health, precision medicine, and life science tools industry. The DxPx Galaxy, while representing but a fraction of the whole start-up universe creates it still creates the sometimes most important and emerging innovations needed. Therefore, we are guiding and connecting the future leaders and innovators, with the experienced professionals that constitute the DxPx Conference of today and award the winners with \$2,000,000 funding.

On behalf of the entire DxPx Team, I would like to thank all our supporters and especially investors, who have joined us in this pioneering award and help us leap into the future of our industry.

Kind regards,
Lena Ehrenpreis
42PLUS1 & DxPx Initiator



We found our 8 finalists out of 338 startup

Welcome on the big stage



Marc Rippen
CEO
alertgy.com



Margaret Magdesian
CEO
anandadevices.com



Daniel Fallscheer
CEO
daslab.app



Natalie Garzorz-Stark
CEO
dermagnostix.com



Tsafir Kolatt
CEO
fertigo-medical.com



Anja Müller
CEO
irubis.com



Ignasi Belda
CEO
miwendo.com



Fouad Al Noor
CEO
thinksono.com



We're over the moon for every helping hand

Big applause for our jurors



Jens Baas

Chairman of the Board



Reetika Bhardwaj

Associate



Rainer Christine

Managing Partner



Matthias Essenpreis

CTO



Eric Fritz

Partner



Sascha Fritz

Investment Principal




Bernd Goergen

Partner



Douwe Jippes

Managing Partner



Christoph Massner

Investment Team



Wouter Meuleman

Partner



Tobias Silberzahn

Partner



Sebastian Stamm

Principal



Erika Stanzl

Associate Partner



Dirk Voelkel

President Innovation



Roy Wiesner

Managing Director



André Zimmermann

Partner

Interested in joining our DxPx galaxy as a juror?

Happy to talk!

l.ehrenpreis@silversky-ls.com

Interview with our US Satellite Award Winner

Good way to kickstart everything

A portrait of a middle-aged man with a grey beard and mustache, wearing a blue polo shirt. He is looking directly at the camera with a slight smile. The background is dark and out of focus.

Hi Marc,
nice to meet you!

So, what is Alertgy?

Alertgy is a company I established after my wife almost went into a low-blood sugar coma. I realized that there were no devices that would allow me to know if she would have a similar incident, at the time. So, I founded Alertgy to develop the first wearable non-invasive blood glucose monitor alert system; and now we have one.

You are our first ever 42PLUS1 Satellite Award Winner, how do you feel about that

I am really grateful to have been invited to participate in and honored by the victory, as I feel the competition was fierce.[...]

What is Alertgy up to, at the moment?

We are currently getting ready to start our clinical regulatory trials in Germany and the USA. [...] Our goal is to launch the business in the USA & Europe at the same time.

Where do you see Alertgy in the next 5 years?

I see us working with major companies like Roche and Medtronic and bringing this technology to the people that need it.[...]

How would you describe your technology to an everyday person?

Our technology is a lot like an MRI Scanner. With an MRI [...] you have to put your whole body inside of a tube. Instead [...] we have a wristband that basically you put your arm in [...]. It warns you if it's [glucose level] low or high and then [...] will notify your loved ones or emergency contacts, so they can make sure you are taken care of.

Where do you see our DxPx Galaxy in 5 years?

[...] we're basically creating a spectral library on people, that we can go back and look at any time, to see what's happening what's changing in their body. [...]

What would the next step for Alertgy be if you were to win the funding?

[...] Next, we look at other things we can bring analyzing people's individual body chemistries.

What are you looking forward to, coming to Dusseldorf, besides winning?

[...] I'm looking forward to seeing my relatives who live in Germany and enjoying a good cold beer and some "Schweinebraten" or "Sauerbraten", and I'm in heaven!

Thank you very much for this interview, Marc.

You're welcome, I appreciate the opportunity and look forward to seeing everybody in person in November.

To see the whole interview with Marc – simply go to our YouTube Channel "42PLUS1" or website 42plus1.com.


Marc won the first 42PLUS1 satellite Edition at the DxPx US conference in July 2021. His pitch beat out 7 other finalists to win a wild ticket to the finals of the 42PLUS1 Pitch Awards 2021, on November 16th. SLS Partnering GmbH will cover his travel expenses to the conference.

Here are the other finalists of the US event









You have not enough after 10 hours of DxPx?

Last but not least - our famous **DxPx ROOFTOP AFTERPARTY**



GET TO KNOW BEAUTIFUL DUSSELDORF BY NIGHT

and have a look over the city from our rooftop location.

ENJOY GOOD DRINKS AND HEAVENLY SNACKS

after an eventful day with so many impressions.



NETWORK IN A RELAXED ATMOSPHERE

to once again get the most out of your day.



Nov. 16th
6:30 pm

Location:
me&all Hotel Düsseldorf
Immermannstr. 23
40210 Düsseldorf

Your first Contacts



DxPx Project Manager

JESSICA STOLZENBERG

“Generalist who oversees the organization’s ongoing operations and procedures and being responsible for the efficiency of the overall business.”



DxPx & 42PLUS1 Initiator

LENA EHRENPREIS

“Fostering innovation in healthcare by initiating the 42PLUS1 Pitch Award, after getting to know the startup game with her own company.”

Finally, you can always call or visit our main office in
Dusseldorf:

SLS Partnering GmbH
Dusseldorf, Brunnenstr. 23
+49 211 30270813
info@dpx-conference.com

Save the dates 2022

DxPx EU

on-site: Nov 16th 2022
digital Partnering:
Nov 4th - Nov 15th

DxPx US

on-site: Jul 26th 2022
digital Partnering:
Jul 15th - Jul 25th



World Series of Industry and Investor Partnering Conferences

Meet us

Dec 2021: Slush in Helsinki

Jan 2022 virtually: 39th Annual Healthcare Conference

Meet us

Mar 2022: BIO Europe in Basel

Apr 2022: NLS Days in Malmö

Apr 2022: ECCMID in Lisbon

Your next chance to win \$2,000,000 funding **42PLUS1 US Satellite Event**

May 16th - Jun 27th: Submissions are open

Jul 11th: Finalists Announcement

Jul 26th: 42PLUS1 Satellite Finale

The winner will be invited to the DxPx EU for the 42PLUS1 final

Nov 16th, 2022 in Dusseldorf, Germany

Important Dates for the finale

Sep 5th - Oct 17th: Submissions are open

Oct 31st: Finalists announcement

Imprint

Publisher

SLS Partnering GmbH
Brunnenstr. 23
40023 Düsseldorf
Germany
Phone: +49 211 302 708 13
info@sls-partnering.com
www.sls-partnering.com



Editing and design

SLS Partnering GmbH
Mirko Stange, Lena Ehrenpreis

Supported by





ENABLING COMPLEX SOLUTION ANALYTICS

A NEW QC GOLD STANDARD FOR CELL-THERAPIES



FAST



AUTOMATED



COMPLEX SAMPLES



STABLE



LABEL-FREE



MULTIPLEX

Contact us about our
EARLY ACCESS PROGRAM
info@lino-biotech.com

www.lino-biotech.com

We would like to thank all our partners and sponsors



Knowledge Partner



Gold Sponsor



Silver Sponsor



Bronze Sponsor



MC SERVICES



Media Partner